MAPT and Alzheimer disease: While the above‐cited work reflects a growing interest in assessing the amyloid and tau biomarker status through optimized latent representations from the sMRI modality, to our knowledge, no research has examined these latent representations as surrogate or proxy‐markers for AD detection and risk prediction.